改善Treg选择性和稳定性用于糖尿病类型1治疗:对前景技术的复杂方法
Andrei A Riabinin1, Dmitry D Zhdanov1,2,3, Varvara G Blinova1,2
1Koltzov Institute of Developmental Biology of Russian Academy of Sciences, 26 Vavilov Street, Moscow 119334, Russia.
Cells
|November 26, 2025
概括
CAR-Tregs对1型糖尿病 (T1D) 免疫疗法有希望. 研究了分子策略,以稳定Treg细胞对抗T1D.
科学领域:
- 免疫学 免疫学 免疫学
- 内分泌学 在内分泌学.
- 细胞疗法细胞疗法
背景情况:
- 调节性T细胞 (Tregs) 的采用转移是1型糖尿病 (T1D) 的潜在免疫疗法.
- 开发针对胰腺小岛抗原的抗原特异性CAR-Tregs是一个关键的研究领域.
- 在T1D的炎症环境中Treg表型的不稳定性限制了治疗疗效.
研究的目的:
- 审查用于增强Treg稳定性T1D的分子方法.
- 讨论改善CAR-Treg在1型糖尿病中的疗效的策略.
主要方法:
- 细胞因子信号通路 (IL2,IL33/ST2,IL35) 的基因工程.
- 对cAMP级联的调制.
- 对稳定的Treg表达进行FOXP3拼接的管理.
- 应用表观遗传机制来实现持久的Treg标识.
主要成果:
- 经过审查的分子策略解决了Treg在T1D中的不稳定性.
- 确定了增强Treg表型耐久性的途径和机制.
- 提供了改善CAR-Treg稳定性和功能的见解.
结论:
- 分子干预可以稳定Treg细胞对T1D的炎症状况.
- 增强的Treg稳定性对于1型糖尿病中有效的CAR-Treg免疫疗法至关重要.
- 未来的研究应该专注于将这些分子策略转化为临床应用.
更多相关视频
11:31High-Efficiency Generation of Antigen-Specific Primary Mouse Cytotoxic T Cells for Functional Testing in an Autoimmune Diabetes Model
Published on: August 16, 2019
8.3K
14:01Human In Vitro Suppression as Screening Tool for the Recognition of an Early State of Immune Imbalance
Published on: July 22, 2011
15.0K
相关概念视频
01:22Diabetes Mellitus: Overview and Type I Subtype
4.8K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
4.8K
01:15Diabetes: Management and Pharmacotherapy
851
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
851